Accurate Education - Alpha-Lipoic Acid (ALA) for Chronic Pain: A Patient Guide

Nutraceuticals:

Alpha-Lipoic Acid (ALA) for Chronic Pain: A Patient Guide

Alpha-lipoic acid (ALA) is a potent antioxidant that significantly reduces chronic neuropathic pain, particularly diabetic polyneuropathy, by improving nerve function and reducing oxidative stress. Clinical trials show that can be effective for reducing pain symptoms like burning, numbness, and stabbing sensations. It is generally well-tolerated with minimal side effects.

See:

Nutraceutical Patient Guides:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Alpha-Lipoic Acid (ALA) for Chronic Pain: A Patient Guide

1. OVERVIEW

Alpha-lipoic acid (ALA), also known as thioctic acid, is a naturally occurring compound that your body produces in small amounts. It functions as a powerful antioxidant and plays a critical role in energy production by serving as a cofactor for mitochondrial enzymes involved in converting food into cellular energy.[1][2]

What makes ALA unique among antioxidants:

It is both water-soluble and fat-soluble (amphiphilic), allowing it to work in all parts of your cells
It can cross the blood-brain barrier to act directly in the nervous system[3]
It regenerates other antioxidants including vitamins C and E, and glutathione—earning it the nickname “antioxidant of antioxidants”[2][4]
It chelates (binds and removes) heavy metals like iron and copper that can cause oxidative damage[2]
It reduces inflammation by inhibiting NF-κB signaling and NLRP3 inflammasome activation[3]

How ALA Compares to Conventional Medications:

For diabetic peripheral neuropathy, ALA has been studied extensively. A 2022 systematic review found that ALA reduces symptoms of stabbing pain, burning, paresthesia, and numbness compared to placebo.[5] A 2026 meta-analysis of 15 studies found significant improvements in paresthesia, numbness, and pain scores, particularly at 600 mg/day.[6] However, a 2024 Cochrane review using stricter criteria (only studies ≥6 months) found that ALA probably has little or no effect on neuropathy symptoms at 6 months, though it may improve neuropathic deficits.[7] The American Academy of Family Physicians notes that intravenous administration shows more consistent pain improvements than oral dosing.[8]

Overall, ALA is considered a safe and tolerable option with fewer side effects than many conventional neuropathy medications, though its efficacy may be more modest than initially hoped.[8][9]

2. DIETARY SOURCES

ALA is found in small amounts in various foods:

Organ meats: Liver, kidney, heart (highest concentrations)
Red meat: Beef, lamb
Vegetables: Spinach, broccoli, tomatoes, Brussels sprouts, peas
Yeast: Brewer’s yeast[1][10]

Important Bioavailability Note: Dietary sources provide only small amounts of ALA (micrograms), far below therapeutic doses (hundreds of milligrams). Supplemental ALA has approximately 30% bioavailability due to hepatic (liver) degradation, reduced solubility, and instability in stomach acid.[1] The R-enantiomer (R-ALA) shows better absorption than the S-enantiomer or racemic mixtures.[1][11] Taking ALA on an empty stomach improves absorption. Newer formulations using cyclodextrin complexes can increase bioavailability by 2.5-fold.[11]

3. INDICATIONS FOR NUTRACEUTICAL SUPPLEMENTATION

Pain Conditions with Moderate to High Quality Evidence:

Diabetic Peripheral Neuropathy (Moderate Quality Evidence)

A 2022 systematic review and meta-analysis found ALA significantly reduced Total Symptom Score (TSS) including stabbing pain, burning, paresthesia, and numbness compared to placebo[5]
A 2023 meta-analysis of 10 RCTs (1,242 patients) showed dose-dependent improvements in TSS and global satisfaction scores with oral ALA[12]
A 2026 meta-analysis of 15 studies found significant improvements in paresthesia (SMD = -1.04), numbness, and pain scores, especially at 600 mg/day[6]
The ALADIN study showed 600 mg IV daily for 3 weeks significantly reduced symptoms[13]
However, a 2024 Cochrane review found ALA probably has little or no effect on symptoms at 6 months in longer-term studies[7]

Other Pain Conditions (Low-Moderate Quality Evidence)

Carpal tunnel syndrome: Systematic review showed efficacy[5]
Burning mouth syndrome: Clinical trials demonstrated benefit[5]
Headache/Migraine: Some evidence of efficacy[5]
Idiopathic pain: A 2021 RCT (210 patients) found significant reductions in pain scores for neuropathic pain, arthralgia, and myalgia of unknown etiology at 400–800 mg/day[14]
Complex Regional Pain Syndrome (CRPS): Preclinical evidence shows ALA reduces mechanical and cold allodynia[15]

Fibromyalgia (Negative Evidence)

The IMPALA trial (2021) found no significant benefit of ALA over placebo for fibromyalgia pain[16]
The CADENCE trial (2023) found no additive benefit of combining ALA with pregabalin for fibromyalgia[17]

4. NUTRACEUTICAL’S IMPACT ON PAIN CONDITION

ALA addresses the underlying pathophysiology of diabetic neuropathy and other nerve damage through multiple mechanisms:

Microvascular Effects:

Improves blood flow to peripheral nerves by enhancing microcirculation[12]
Reduces endothelial dysfunction
Improves oxygen delivery to damaged nerves

Metabolic Effects:

Serves as a cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, improving cellular energy production[1]
May improve insulin sensitivity and glucose metabolism[18][19]
Reduces advanced glycation end products (AGEs) that damage nerves in diabetes

Nerve Protection:

Prevents lipid peroxidation in nerve membranes[20]
Chelates transition metals (iron, copper) that catalyze oxidative damage[2]
Supports nerve fiber integrity and function

Note: While ALA improves neuropathy symptoms, evidence for actual nerve regeneration or improvement in nerve conduction studies is limited.[7][6]

5. NUTRACEUTICAL’S IMPACT ON PAIN PROCESSING

Pain processing refers to how pain signals are processed from the initial damaged tissue source of pain through the nerves and spinal cord to the brain and then down the spinal cord again. Nutraceuticals offer potential benefit for reducing the severity of the pain experience by acting at various levels of pain processing. These benefits are independent of the benefits the nutraceutical offers at the source of pain.

Level 1: Peripheral Pain Receptor (Nociception Transduction)

ALA modulates pain at the very first step—where nociceptors convert tissue damage into electrical signals:

1. Inhibits T-type calcium channels (CaV3.2) in sensory neurons, reducing nociceptor excitability[21]. This effect occurs through oxidation of specific thiol residues on the channel[21]
2. Reduces sensitivity to noxious thermal and mechanical stimuli (demonstrated in CaV3.2 knockout mice studies)[21]
3. Decreases reactive oxygen species at nerve terminals that can sensitize pain receptors[15]

Level 2: Primary Afferent Transmission to Spinal Cord

ALA supports healthy signal transmission along peripheral nerves:

1. Protects nerve fibers from oxidative damage during signal conduction
2. Maintains myelin sheath integrity through antioxidant effects
3. Reduces NADPH oxidase activity in the sciatic nerve, decreasing oxidative stress[15]
4. Improves nerve conduction by supporting mitochondrial function in nerve axons

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

ALA has significant effects at the spinal cord level where pain signals are first processed:

1. Reduces spinal cord oxidative stress (decreased hydrogen peroxide, SOD, and NADPH oxidase activity)[15]
2. Inhibits astrocyte activation (reduced GFAP expression) in the spinal cord dorsal horn[15]
3. Modulates Nrf2 (nuclear factor erythroid 2-related factor 2), the master regulator of antioxidant responses[15]
4. Reduces spinal neuroinflammation that contributes to central sensitization[15]

Level 4: Ascending Spinal Pathways and Supraspinal Processing

ALA crosses the blood-brain barrier to affect higher pain processing centers:

1. Reduces neuroinflammation in supraspinal structures[3][22]
2. Inhibits microglial activation and shifts microglia from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype[3]
3. Suppresses NLRP3 inflammasome activation in the brain[3]
4. Decreases pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in CNS tissues[3][22]

Level 5: Brain Cortical Processing and Pain Perception

ALA modulates the conscious experience of pain through:

1. Neuroprotective effects in cortical regions involved in pain perception[23]
2. Reduction of oxidative stress in brain tissue that can amplify pain perception
3. Modulation of neurotransmitter systems involved in pain processing
4. Potential effects on mood and cognitive function that influence pain experience[24]

Level 6: Descending Pain Modulation

ALA supports the brain’s ability to inhibit pain signals:

1. Increases brain-derived neurotrophic factor (BDNF), which supports descending inhibitory pathways[22]
2. Reduces neuroinflammation in brainstem nuclei that control descending modulation[22]
3. Supports mitochondrial function in descending pathway neurons
4. Modulates NF-κB signaling, which influences descending pain control[2]

6. BENEFITS FOR PAIN SENSITIZATION

Peripheral Sensitization: MODERATE Quality Evidence

ALA reduces peripheral sensitization through:

1. Direct inhibition of T-type calcium channels (CaV3.2) on sensory neurons[21]
2. Reduction of oxidative stress at peripheral nerve terminals[25][15]
3. Decreased production of reactive oxygen species that sensitize nociceptors[15]
4. Protection of peripheral nerve fibers from inflammatory damage[20]
5. Chelation of metals that contribute to oxidative nerve damage[2]

Central Sensitization: MODERATE Quality Evidence

ALA addresses central sensitization through:

1. Crosses the blood-brain barrier to act directly in the CNS[3]
2. Reduces spinal cord astrocyte and microglial activation[15][3]
3. Inhibits NLRP3 inflammasome activation in the CNS[3]
4. Decreases spinal cord oxidative stress markers[15]
5. Modulates Nrf2 antioxidant pathway in the spinal cord[15]
6. Shifts microglial phenotype from pro-inflammatory (M1) to anti-inflammatory (M2)[3]
7. Increases BDNF levels, supporting healthy pain modulation[22]

7. NUTRACEUTICAL’S IMPACT ON THE 4 DRIVING FORCES OF CHRONIC PAIN

1. Systemic Inflammation: MODERATE EFFECT

ALA reduces systemic inflammation through:

1. Inhibition of NF-κB signaling pathway[2][3]
2. Reduction of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)[3][22]
3. Decreased C-reactive protein (hs-CRP) at higher doses (1,200 mg/day)[19]
4. Modulation of immune cell function[3]

2. Neuroinflammation: STRONG EFFECT

ALA has notable effects on brain and spinal cord inflammation:

1. Crosses the blood-brain barrier to act directly in the CNS[3]
2. Inhibits microglial activation and promotes M2 (anti-inflammatory) phenotype[3]
3. Suppresses NLRP3 inflammasome activation[3]
4. Reduces astrocyte reactivity in the spinal cord[15]
5. Decreases neuroinflammatory cytokines in brain tissue[22]
6. Increases BDNF, supporting neuronal health[22]

3. Oxidative Stress: STRONG EFFECT (Primary Mechanism)

This is ALA’s primary mechanism of action:

1. Direct scavenging of reactive oxygen species (ROS)[2][4]
2. Regenerates other antioxidants (vitamins C, E, glutathione, CoQ10)[2][4]
3. Chelates pro-oxidant metals (iron, copper)[2]
4. Activates Nrf2 pathway, upregulating endogenous antioxidant enzymes[15]
5. Reduces lipid peroxidation in nerve membranes[20]
6. Decreases hydrogen peroxide and superoxide production[15]
7. Both oxidized (ALA) and reduced (DHLA) forms are active antioxidants[2][4]

4. Mitochondrial Dysfunction: STRONG EFFECT

ALA supports mitochondrial function through:

1. Serves as essential cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase[1][2]
2. Improves mitochondrial energy production (ATP synthesis)
3. Protects mitochondrial membranes from oxidative damage
4. Supports electron transport chain function
5. Reduces mitochondrial ROS production

8. DOSING, TIMING, DURATION AND ADMINISTRATION

Recommended Dosing:

Diabetic neuropathy (maintenance)
1. Dose 600 mg/day
2. Duration: ≥3 months; ongoing
Diabetic neuropathy (higher dose):
1. Dose: 600–1,800 mg/day
2. Duration: ≥3 months; ongoing
Idiopathic Pain
1. Dose: 400–800 mg/day
2. Duration: ≥2 months; ongoing
General Antioxidant Support
1. Dose: 300–600 mg/day
2. Duration: ≥2 months

Key Dosing Points:

1. 600 mg/day is the most studied and recommended dose for diabetic neuropathy[6][26][27]
2. A dose-response relationship exists: higher doses (1,200–1,800 mg/day) may provide greater symptom relief but with more GI side effects[12][13]
3. Oral 600 mg once daily appears equivalent to IV infusions for symptom improvement[26]
4. Higher doses (800–1,200 mg/day) showed greater improvements in lipid profile and glycemic parameters[19]

Timing:

1. Take on an empty stomach (30–60 minutes before meals) for optimal absorption[1]
2. Food significantly reduces ALA absorption
3. Can divide doses if GI upset occurs (e.g., 300 mg twice daily)

Duration of Onset:

1. IV treatment: Symptom improvement may begin within 1–3 weeks[13]
2. Oral treatment: Typically 3–5 weeks for noticeable symptom improvement
3. Optimal effects: 3–6 months of consistent use
4. Long-term use (4 years) has been shown to be safe[19]

9. FORMULATION CONSIDERATIONS

Enantiomers:

1. ALA exists as two mirror-image forms: R-ALA (natural) and S-ALA (synthetic)
2. Most supplements contain racemic (50/50 R and S) ALA
3. R-ALA has superior bioavailability and is the biologically active form[1][11]
4. R-ALA supplements may be more effective but are typically more expensive

Enhanced Formulations:

1. R-ALA/γ-cyclodextrin complex: 2.5-fold higher bioavailability than standard R-ALA[11]
2. Liquid formulations: Higher plasma concentrations than solid forms[1]
3. Sustained-release formulations: May improve tolerability

Quality Considerations:

1. Choose products from reputable manufacturers
2. Look for third-party testing (USP, NSF, ConsumerLab)
3. R-ALA products should be stabilized (R-ALA alone is unstable)
4. Avoid products exposed to heat or moisture (ALA degrades)

10. SYNERGIES WITH OTHER PAIN MEDICATIONS AND NUTRACEUTICALS

Nutraceuticals:

1. Acetyl-L-carnitine (ALC): Both target mitochondrial function and oxidative stress; complementary mechanisms for neuropathy. A 2025 study found a combination of ALC, PEA, and ALA (with Boswellia) significantly improved acute low back pain.[28][29]
2. Palmitoylethanolamide (PEA): Complementary anti-inflammatory and analgesic effects[28]
3. B vitamins: Support nerve health; vitamin B complex plus ALA may be effective for burning mouth syndrome[29]
4. Coenzyme Q10: Both support mitochondrial function
5. Vitamin E: ALA regenerates vitamin E; complementary antioxidant effects
6. Glutathione precursors (NAC): ALA regenerates glutathione

Conventional Treatments:

1. May complement standard neuropathy medications (gabapentin, pregabalin, duloxetine)
2. The CADENCE trial found ALA can be safely combined with pregabalin without increased side effects, though no additive benefit was seen for fibromyalgia[17]
3. Can be used alongside diabetes medications; may improve insulin sensitivity[18]
4. Vitamin B complex plus gabapentin plus ALA may be beneficial for neuropathic pain[29]

11. DRUG INTERACTIONS

Potential Interactions:

1. Diabetes medications (insulin, metformin, sulfonylureas): ALA may enhance blood sugar lowering effects; monitor glucose closely and adjust doses as needed[18]
2. Thyroid medications (levothyroxine): ALA may affect thyroid hormone levels; take at least 4 hours apart
3. Chemotherapy agents: ALA’s antioxidant effects could theoretically interfere with some chemotherapy drugs; consult oncologist before use
4. Alcohol: May reduce ALA effectiveness; excessive alcohol depletes thiamine which works with ALA

Generally Safe Combinations:

1. No significant interactions with most common pain medications
2. Safe with gabapentinoids (gabapentin, pregabalin)[17]
3. Safe with standard antihypertensive medications

Always inform your healthcare provider about all supplements you take.

12. SAFETY AND CONTRAINDICATIONS

Generally Well-Tolerated: A 2020 meta-analysis of 71 clinical studies (4,749 subjects) found ALA supplementation was not associated with increased risk of any adverse events compared to placebo, even in patients with diabetes, cardiovascular disease, neurological disorders, pregnancy, or renal impairment.[9]

Possible Side Effects (usually mild and dose-related):

1. Gastrointestinal: nausea, vomiting, diarrhea, abdominal discomfort (most common)
2. Skin: rash, itching (uncommon)
3. Headache, dizziness
4. Hypoglycemia (in diabetic patients)
5. Hypotension (rare)[19]

Serious but Rare Adverse Events:

1. Insulin Autoimmune Syndrome (IAS): Rare cases reported, primarily in individuals with specific HLA genotypes (more common in Asian populations). Presents with hypoglycemia due to insulin autoantibodies.[18][30]
2. Allergic reactions: Rare cases of angioedema and anaphylaxis reported[30]
3. Skin reactions: Unpredictable skin reactions have been reported in post-marketing surveillance[30]

Contraindications:

1. Known allergy to ALA or thioctic acid
2. Active thiamine (vitamin B1) deficiency (ALA may worsen; supplement thiamine first)
3. Caution in patients prone to hypoglycemia

Who Should Use Caution:

1. Diabetic patients on insulin or oral hypoglycemics (monitor blood sugar closely)
2. Patients with thyroid disorders
3. Those scheduled for surgery (discontinue 2 weeks prior due to blood sugar effects)
4. Patients receiving chemotherapy (consult oncologist)

13. SPECIAL CONSIDERATIONS / TIPS

Empty stomach: Take 30–60 minutes before meals for best absorption
Start low: Begin with 300–600 mg/day and increase gradually to minimize GI side effects
Be patient: Allow 4–6 weeks for symptom improvement; full benefits may take 3–6 months
R-ALA advantage: Consider R-ALA formulations for better bioavailability, especially if standard ALA is ineffective
Blood sugar monitoring: If diabetic, monitor glucose more frequently when starting ALA
Quality matters: Choose stabilized formulations from reputable manufacturers
Storage: Keep in cool, dry place; ALA degrades with heat and moisture
IV option: For severe symptoms, initial IV treatment (600 mg/day for 3 weeks) may provide faster relief before transitioning to oral maintenance[31][13]
Combination approach: Consider combining with acetyl-L-carnitine for complementary mitochondrial and antioxidant support[28][29]

14. COSTS

Standard racemic ALA (600 mg capsules): $10–25 per month
R-ALA formulations: $25–50 per month
Enhanced bioavailability formulations (cyclodextrin complex): $40–70 per month
IV infusions (if available): Significantly more expensive; typically administered in clinical settings

ALA is widely available over-the-counter and is relatively affordable compared to many prescription neuropathy medications.

Remember: ALA works best as part of a comprehensive pain management plan that includes proper medical care, blood sugar control (for diabetic neuropathy), physical activity, stress management, and healthy nutrition. While ALA has a strong safety profile and may help reduce neuropathy symptoms, the evidence for dramatic improvements is mixed. Always discuss any new supplement with your healthcare provider before starting, especially if you have diabetes or are taking medications that affect blood sugar.

References

Insights on the Use of Α-Lipoic Acid for Therapeutic Purposes. Salehi B, Berkay Yılmaz Y, Antika G, et al. Biomolecules. 2019;9(8):E356. doi:10.3390/biom9080356.
Lipoic Acid – Biological Activity and Therapeutic Potential. Gorąca A, Huk-Kolega H, Piechota A, et al. Pharmacological Reports : PR. 2011;63(4):849-58. doi:10.1016/s1734-1140(11)70600-4.
Effects of Α-Lipoic Acid on LPS-induced Neuroinflammation and NLRP3 Inflammasome Activation Through the Regulation of BV-2 Microglial Cells Activation. Kim SM, Ha JS, Han AR, Cho SW, Yang SJ. BMB Reports. 2019;52(10):613-618.
Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits. Superti F, Russo R. Antioxidants (Basel, Switzerland). 2024;13(10):1228. doi:10.3390/antiox13101228.
Evaluation of the Analgesic Effect of Ɑ-Lipoic Acid in Treating Pain Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cassanego G, Rodrigues P, De Freitas Bauermann L, Trevisan G. Pharmacological Research. 2022;177:106075. doi:10.1016/j.phrs.2022.106075.
Effectiveness of Alpha Lipoic Acid Supplementation on Biochemical, Clinical, and Inflammatory Parameters in Patients With Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. Salinas AV, Caroca TM, Santibáñez FP, et al. Diabetes & Metabolic Syndrome. 2026;20(2):103374. doi:10.1016/j.dsx.2026.103374.
Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy. Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. The Cochrane Database of Systematic Reviews. 2024;1:CD012967. doi:10.1002/14651858.CD012967.pub2.
Diabetic Peripheral Neuropathy: Prevention and Treatment. Bragg S, Marrison ST, Haley S. American Family Physician. 2024;109(3):226-232.
Safety Evaluation of Α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. Fogacci F, Rizzo M, Krogager C, et al. Antioxidants (Basel, Switzerland). 2020;9(10):E1011. doi:10.3390/antiox9101011.
Antistress and Antiaging Potentials of Alpha-Lipoic Acid: Insights From Cell Culture-Based Experiments. Wadhwa R, Hegde M, Zhang H, et al. Applied Biochemistry and Biotechnology. 2024;196(12):8791-8808. doi:10.1007/s12010-024-04994-4.
Bioavailability of an R-Α-Lipoic Acid/Γ-Cyclodextrin Complex in Healthy Volunteers. Ikuta N, Okamoto H, Furune T, et al. International Journal of Molecular Sciences. 2016;17(6):E949. doi:10.3390/ijms17060949.
Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Hsieh RY, Huang IC, Chen C, Sung JY. Nutrients. 2023;15(16):3634. doi:10.3390/nu15163634.
Alpha-Lipoic Acid in the Treatment of Diabetic Peripheral and Cardiac Autonomic Neuropathy. Ziegler D, Gries FA. Diabetes. 1997;46 Suppl 2:S62-6. doi:10.2337/diab.46.2.s62.
Safety and Efficacy of Alpha-Lipoic Acid Oral Supplementation in the Reduction of Pain With Unknown Etiology: A Monocentric, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Esposito C, Ugo Garzarella E, Santarcangelo C, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2021;144:112308. doi:10.1016/j.biopha.2021.112308.
Alpha-Lipoic Acid Reduces Nociception by Reducing Oxidative Stress and Neuroinflammation in a Model of Complex Regional Pain Syndrome Type I in Mice. Rodrigues P, Cassanego GB, Peres DS, et al. Behavioural Brain Research. 2023;459:114790. doi:10.1016/j.bbr.2023.114790.
Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Alpha-Lipoic Acid for the Treatment of Fibromyalgia Pain: The IMPALA Trial. Gilron I, Robb S, Tu D, et al. Pain. 2021;162(2):561-568. doi:10.1097/j.pain.0000000000002028.
Combination Analgesic Development for Enhanced Clinical Efficacy (The CADENCE Trial): A Double-Blind, Controlled Trial of an Alpha-Lipoic Acid-Pregabalin Combination for Fibromyalgia Pain. Gilron I, Robb S, Tu D, et al. Pain. 2023;164(8):1783-1792. doi:10.1097/j.pain.0000000000002875.
Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features. Capece U, Moffa S, Improta I, et al. Nutrients. 2022;15(1):18. doi:10.3390/nu15010018.
Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention. Derosa G, D’Angelo A, Preti P, Maffioli P. Drug Design, Development and Therapy. 2020;14:5367-5374. doi:10.2147/DDDT.S280802.
Potential for Novel Therapeutic Uses of Alpha Lipoic Acid. Fasipe B, Faria A, Laher I. Current Medicinal Chemistry. 2023;30(35):3942-3954. doi:10.2174/0929867329666221006115329.
Molecular Mechanisms of Lipoic Acid Modulation of T-Type Calcium Channels in Pain Pathway. Lee WY, Orestes P, Latham J, et al. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2009;29(30):9500-9. doi:10.1523/JNEUROSCI.5803-08.2009.
Alpha-Lipoic Acid Reduces Neuroinflammation and Oxidative Stress Induced by Dapsone in an Animal Model. Gomes BAQ, Santos SMD, Gato LDS, et al. Nutrients. 2025;17(5):791. doi:10.3390/nu17050791.
Α-Lipoic Acid, Functional Fatty Acid, as a Novel Therapeutic Alternative for Central Nervous System Diseases: A Review. Seifar F, Khalili M, Khaledyan H, et al. Nutritional Neuroscience. 2019;22(5):306-316. doi:10.1080/1028415X.2017.1386755.
Alpha-Lipoic Acid: An Antioxidant With Anti-Aging Properties for Disease Therapy. Shanaida M, Lysiuk R, Mykhailenko O, et al. Current Medicinal Chemistry. 2025;32(1):23-54. doi:10.2174/0109298673300496240416114827.
Alpha-Lipoic Acid as an Antioxidant Strategy for Managing Neuropathic Pain. Viana MDM, Lauria PSS, Lima AA, et al. Antioxidants (Basel, Switzerland). 2022;11(12):2420. doi:10.3390/antiox11122420.
2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV. Bruce RD, Merlin J, Lum PJ, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2017;65(10):e1-e37. doi:10.1093/cid/cix636.
A Case for Alpha-Lipoic Acid as an Alternative Treatment for Diabetic Polyneuropathy. Nguyen N, Takemoto JK. Journal of Pharmacy & Pharmaceutical Sciences : A Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques. 2018;21(1s):177s-191s. doi:10.18433/jpps30100.
Unlocking Relief: Investigating the Impact of a Fixed Combination of Acetyl-L-Carnitine and Palmitoylethanolamide on Traumatic Acute Low Back Pain. Cominacini M, Valenti MT, Braggio M, et al. European Journal of Neurology. 2025;32(8):e70334. doi:10.1111/ene.70334.
Non-Drug Pain Relievers Active on Non-Opioid Pain Mechanisms. Marchesi N, Govoni S, Allegri M. Pain Practice : The Official Journal of World Institute of Pain. 2022;22(2):255-275. doi:10.1111/papr.13073.
Assessment of Adverse Reactions to Α-Lipoic Acid Containing Dietary Supplements Through Spontaneous Reporting Systems. Gatti M, Ippoliti I, Poluzzi E, et al. Clinical Nutrition (Edinburgh, Scotland). 2021;40(3):1176-1185. doi:10.1016/j.clnu.2020.07.028.
Treatment of Symptomatic Diabetic Polyneuropathy With the Antioxidant Alpha-Lipoic Acid: A 7-Month Multicenter Randomized Controlled Trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Diabetes Care. 1999;22(8):1296-301. doi:10.2337/diacare.22.8.1296.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.